BRIEF published on 02/06/2026 at 07:35, 3 months 7 days ago Sensorion to Participate in ARO 49th Annual Midwinter Meeting Biotechnology Gene Therapy Sensorion Hearing Loss ARO Meeting
PRESS RELEASE published on 02/06/2026 at 07:30, 3 months 7 days ago Informations privilégiées / Autres communiqués Sensorion participe à la 49ème rencontre annuelle de l’ARO pour présenter sa nouvelle thérapie génique SENS-601 pour la surdité autosomique récessive non syndromique 1A Thérapie Génique Sensorion Perte Auditive Surdité ARO
PRESS RELEASE published on 02/06/2026 at 07:30, 3 months 7 days ago Inside Information / Other news releases Sensorion to present SENS-601 gene therapy at ARO 49th Annual Midwinter Meeting in Puerto Rico Gene Therapy Sensorion Hearing Loss SENS-601 ARO 49th Annual Midwinter Meeting
BRIEF published on 01/28/2026 at 07:48, 3 months 16 days ago Sensorion obtient un financement de 60 millions d'euros pour faire progresser les thérapies contre la perte auditive Thérapie Génique Sensorion Perte Auditive Financement Des Biotechnologies Investissements Sanofi
BRIEF published on 01/28/2026 at 07:48, 3 months 16 days ago Sensorion Secures €60 Million Financing to Advance Hearing Loss Therapies Gene Therapy Biotech Financing Sensorion Hearing Loss Sanofi Investment
PRESS RELEASE published on 01/28/2026 at 07:43, 3 months 16 days ago Informations privilégiées / Autres communiqués Sensorion annonce un financement de 60 millions d’euros avec Sanofi et d'autres investisseurs pour développer ses thérapies géniques. Trésorerie prévue jusqu'à mi-2027 Financement Trésorerie Thérapie Génique Sanofi Sensorion
PRESS RELEASE published on 01/28/2026 at 07:43, 3 months 16 days ago Inside Information / Other news releases Sensorion announces €60 million financing with a €20M strategic investment from Sanofi and support from global healthcare specialists to advance genetic medicine pipeline. Cash runway extended until H1 2027 Financing Sanofi Sensorion Genetic Medicine Healthcare Specialists
BRIEF published on 12/19/2025 at 07:35, 4 months 25 days ago Sensorion présentera ses services lors de la conférence JP Morgan Healthcare. Biotechnologie Thérapie Génique JP Morgan Perte Auditive SENS-401
BRIEF published on 12/19/2025 at 07:35, 4 months 25 days ago Sensorion to Present at J.P. Morgan Healthcare Conference Biotechnology Gene Therapy J.P. Morgan Hearing Loss SENS-401
PRESS RELEASE published on 12/19/2025 at 07:30, 4 months 25 days ago Inside Information / Other news releases Sensorion to present at 44th Annual J.P. Morgan Healthcare Conference with focus on novel therapies for hearing loss disorders. CEO Nawal Ouzren to lead presentation Biotechnology Sensorion Hearing Loss Disorders J.P. Morgan Healthcare Conference Thérapies
Published on 05/14/2026 at 04:15, 2 hours 36 minutes ago Battery X Metals Announces Corporate Awareness Engagement
Published on 05/14/2026 at 03:15, 3 hours 36 minutes ago Jaguar Delivers Strong Adjusted Earnings and Strategic Production Restart of MTL (Turmalina Mine) in Q1 2026
Published on 05/13/2026 at 23:30, 7 hours 21 minutes ago CCL Industries Announces Results for 2026 First Quarter
Published on 05/14/2026 at 03:20, 3 hours 30 minutes ago TCL Electronics (01070.HK) Maintains Strong Growth in Q1 2026
Published on 05/14/2026 at 01:05, 5 hours 45 minutes ago THE ROYAL MINT SHINES A LIGHT ON PINK FLOYD WITH FIRST EVER UK COMMEMORATIVE COIN
Published on 05/13/2026 at 22:20, 8 hours 30 minutes ago Rumble Announces Initial Results of Exchange Offer for Northern Data
Published on 05/13/2026 at 18:02, 12 hours 48 minutes ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
Published on 05/13/2026 at 18:00, 12 hours 51 minutes ago ALTAREIT - Assemblée Générale Mixte du 4 juin 2026 - Modalités de mise à disposition des documents préparatoires
Published on 05/13/2026 at 17:45, 13 hours 6 minutes ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
